MET and lung adenocarcinoma: We tested an alternative lung adenocarcinoma cell line, H3122, and inhibiting MET with Crizotinib reduced mature LRP6, an effect that was almost abolished when ZNRF3/RNF43 where siRNA-inhibited (Figure 5—figure supplement 1A).